Zosano Pharma Corporation [NASDAQ: ZSAN] closed the trading session at $1.07 on 03/04/21. The day’s price range saw the stock hit a low of $1.00, while the highest price level was $1.18. The company report on March 2, 2021 that Zosano Pharma to Present at the H.C. Wainwright Global Life Sciences Conference.
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Global Life Sciences Conference which will be available on Tuesday, March 9, 2021 at 7:00 am ET.
A webcast of the event will be available on the company’s website at http://ir.zosanopharma.com/events-presentations. The archived webcast will remain available for 30 days following the date of the presentation.
The stocks have a year to date performance of 103.00 percent and weekly performance of -17.69 percent. The stock has been moved at -30.07 percent over the last six months. The stock has performed 10.31 percent around the most recent 30 days and changed 73.93 percent over the most recent 3-months.
If compared to the average trading volume of 11.35M shares, ZSAN reached to a volume of 8205749 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Zosano Pharma Corporation [ZSAN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ZSAN shares is $1.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ZSAN stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Zosano Pharma Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 17, 2019. While these analysts kept the previous recommendation, Piper Jaffray raised their target price to Overweight. The new note on the price target was released on March 24, 2017, representing the official price target for Zosano Pharma Corporation stock. On November 11, 2015, analysts decreased their price target for ZSAN shares from 11 to 7.
The Average True Range (ATR) for Zosano Pharma Corporation is set at 0.21 The Price to Book ratio for the last quarter was 1.51.
ZSAN stock trade performance evaluation
Zosano Pharma Corporation [ZSAN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -17.69. With this latest performance, ZSAN shares gained by 10.31% in over the last four-week period, additionally sinking by -30.07% over the last 6 months – not to mention a rise of 21.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZSAN stock in for the last two-week period is set at 41.55, with the RSI for the last a single of trading hit 33.70, and the three-weeks RSI is set at 46.03 for Zosano Pharma Corporation [ZSAN]. The present Moving Average for the last 50 days of trading for this stock 1.0747, while it was recorded at 1.2300 for the last single week of trading, and 0.9871 for the last 200 days.
Zosano Pharma Corporation [ZSAN]: An insightful look at the core fundamentals
Return on Total Capital for ZSAN is now -141.21, given the latest momentum, and Return on Invested Capital for the company is -168.41. Return on Equity for this stock declined to -267.52, with Return on Assets sitting at -102.35. When it comes to the capital structure of this company, Zosano Pharma Corporation [ZSAN] has a Total Debt to Total Equity ratio set at 189.02. Additionally, ZSAN Total Debt to Total Capital is recorded at 65.40, with Total Debt to Total Assets ending up at 47.13. Long-Term Debt to Equity for the company is recorded at 128.20, with the Long-Term Debt to Total Capital now at 44.36.
Reflecting on the efficiency of the workforce at the company, Zosano Pharma Corporation [ZSAN] managed to generate an average of -$671,232 per employee.Zosano Pharma Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.40 and a Current Ratio set at 3.40.
Earnings per share (EPS) analysis for Zosano Pharma Corporation [ZSAN] stock
With the latest financial reports released by the company, Zosano Pharma Corporation posted -0.45/share EPS, while the average EPS was predicted by analysts to be reported at -0.47/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZSAN.
Zosano Pharma Corporation [ZSAN]: Insider Ownership positions
There are presently around $12 million, or 14.00% of ZSAN stock, in the hands of institutional investors. The top three institutional holders of ZSAN stocks are: VANGUARD GROUP INC with ownership of 3,542,848, which is approximately 11.244% of the company’s market cap and around 0.36% of the total institutional ownership; AISLING CAPITAL MANAGEMENT LP, holding 2,718,226 shares of the stock with an approximate value of $2.91 million in ZSAN stocks shares; and BLACKROCK INC., currently with $1.18 million in ZSAN stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Zosano Pharma Corporation stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 14 institutional holders increased their position in Zosano Pharma Corporation [NASDAQ:ZSAN] by around 1,290,418 shares. Additionally, 23 investors decreased positions by around 3,432,841 shares, while 10 investors held positions by with 6,192,563 shares. The mentioned changes placed institutional holdings at 10,915,822 shares, according to the latest SEC report filing. ZSAN stock had 6 new institutional investments in for a total of 366,519 shares, while 15 institutional investors sold positions of 1,696,466 shares during the same period.